Therapy News and Research

RSS

Minimally invasive valve repair lowers hospitalizations in heart failure patients

At two years of follow-up, patients with a poorly functioning tricuspid valve in the heart who received optimal medical therapy plus a minimally invasive procedure using a clip to repair the valve were significantly less likely to die, have a heart attack or stroke and 40% less likely to be hospitalized for heart failure compared with similar patients who were randomly assigned to optimal medical therapy alone.

29 Mar 2026

Noninvasive lung impedance monitoring improves outcomes in HFpEF patients

Treatment management guided by the use of a noninvasive device to monitor fluid accumulation in the lungs substantially reduced hospitalizations and deaths among patients with heart failure with preserved ejection fraction (HFpEF), according to research presented at the American College of Cardiology's Annual Scientific Session (ACC.26).

29 Mar 2026

Trial shows mavacamten benefits adolescents with obstructive heart condition

Adolescent patients with obstructive hypertrophic cardiomyopathy (HCM) who received the drug mavacamten saw a significant improvement in left ventricular outflow tract (LVOT) gradient, a measure of blood flow obstruction in the heart, compared with those who received a placebo, according to a small study presented at the American College of Cardiology's Annual Scientific Session (ACC.26).

29 Mar 2026

APOE4 alters brain immunity and cognition differently in females and males

APOE4 drove sex-specific changes in meningeal immunity, lymphatic drainage, brain lipids, neuroinflammation, and cognition in mouse models, with females showing greater inflammatory and cognitive vulnerability. Suppressing innate immunity improved some cognitive outcomes in female E4/E4 mice but worsened them in male E4/E4 mice, underscoring the need for sex-tailored approaches.

29 Mar 2026

Intensive LDL cholesterol-lowering shows major benefits for heart disease patients

Using cholesterol-lowering medications more intensively to achieve a more aggressive target for low-density lipoprotein cholesterol (LDL-C) reduced the rate of major cardiovascular events by one-third among patients with atherosclerotic cardiovascular disease (ASCVD), according to a study presented at the American College of Cardiology's Annual Scientific Session (ACC.26).

28 Mar 2026

Evolocumab reduces cardiac events in high-risk diabetic patients

The cholesterol-lowering therapy evolocumab reduced the risk of major adverse cardiac events by nearly one-third among patients who had no known significant atherosclerosis and had diabetes, according to a study presented at the American College of Cardiology's Annual Scientific Session.

28 Mar 2026

Intensive cholesterol‑lowering therapy reduces first major cardiac event in high‑risk patients with diabetes

Mass General Brigham researchers found that the intensive cholesterol‑lowering therapy evolocumab reduced the risk of a first major cardiovascular event in high‑risk patients who did not have known atherosclerosis (the build-up of plaque inside artery walls) but did have diabetes.

28 Mar 2026

Microaxial flow pump fails to reduce heart damage in STEMI trial

Using a microaxial flow pump prior to and during cardiac stenting procedures for patients with severe heart attacks who don't have cardiogenic shock does not significantly reduce heart damage.

28 Mar 2026

Left atrial appendage closure matches anticoagulants in AFib patients

For patients with non-valvular atrial fibrillation (AFib) who had no contraindications to taking oral anticoagulants, the use of a device to close off the left atrial appendage in the heart—a small pouch where blood can pool and form dangerous clots—was comparable to standard medication therapy in reducing the combined rate of all-cause stroke, cardiovascular death and systemic embolism at three years.

28 Mar 2026

Study reveals immune changes in HIV and HCV coinfected patients

Human immunodeficiency virus (HIV)/hepatitis C virus (HCV) coinfection leads to severe systemic inflammation, increasing non-AIDS morbidity and mortality risk. CD39 ectoenzyme on T-cells, which catalyzes the conversion of pro-inflammatory purines to immunosuppressive adenosine, plays an important role in inflammation control.

28 Mar 2026

HOBIT device improves oxygen supply for drug-producing cells

Implanting living cells as long-term drug producers could transform treatment for numerous diseases, but it is difficult to house the tiny workers in quantities high enough to ensure dosage needs are met while also keeping the cells alive and thriving.

27 Mar 2026

Aging lung cells drive severe inflammation in flu and COVID

Older adults are much more likely to become seriously ill from flu or COVID because aging lung cells can drive excessive immune responses, according to a new study led by researchers at UC San Francisco.

27 Mar 2026

Diverse biobank study links genetics to disease risk and treatment

A new study by UCLA Health published in Cell presents a major advancement in the future of personalized medicine by pinpointing new connections between people's genes, disease risk and medicine response by using a clinically well-characterized and diverse population-represented biobank.

27 Mar 2026

Study reveals how a promising bacterial therapy reduces recurrent bacterial vaginosis

A new study from the Kwon Lab at the Ragon Institute, published in Cell Host & Microbe, provides the most detailed picture yet of how a promising bacterial therapy works to prevent recurrent bacterial vaginosis (BV) and why it works better for some women than others.

27 Mar 2026

Tiny device with engineered cells acts as internal drug factory

A multi-institutional team of scientists, co-led by Northwestern University, has taken a crucial step toward implantable "living pharmacies" - tiny devices containing engineered cells that continuously produce medicines inside the body.

27 Mar 2026

FDA approves first gene therapy for rare pediatric immune disorder

Dr. Donald Kohn has been developing gene therapies for rare pediatric immune disorders for over 30 years.

27 Mar 2026

TENS therapy reduces movement pain and fatigue in fibromyalgia patients

Adding TENS (transcutaneous electrical nerve stimulation) to outpatient physical therapy reduced movement-based pain and fatigue in patients with fibromyalgia, and the effects lasted for at least six months, according to a new study led by researchers at University of Iowa Health Care.

27 Mar 2026

Guselkumab shows minor added benefit for specific Crohn's disease patients

The human monoclonal antibody guselkumab has been approved for certain adults with moderately to severely active ulcerative colitis since April 2025.

27 Mar 2026

Updated heart guidelines urge earlier screening for high blood cholesterol

For the first time since 2018, a clinical guideline from the American College of Cardiology and the American Heart Association for screening and managing blood cholesterol levels has been updated and jointly published in the Journal of the American College of Cardiology and Circulation.

27 Mar 2026